In MM.1S xenografts, BSO+L-PAM induced CRs in all 10 mice and 1 mouse had a maintained CR (MCR) (CR100 days)
Predicting anticancer peptides with Chous pseudo amino acid composition and investigating their mutagenicity via Ames test
Disclosures: Eveline Gart: Sagimet: Independent Contractor, Mead Johnson: Independent Contractor, Lars Verschuren: Nothing to Disclose, Anne Mak: Nothing to Disclose, Andre Boonstra: Gilead: Grant/Research Support, Janssen Pharma: Grant/Research Support, GSK: Grant/Research Support, Fujirebio: Grant/Research Support, Joanne Verheij: Nothing to Disclose, Lise Lotte Gluud: Nothing to Disclose, Adriaan Holleboom: Nothing to Disclose, Maarten Tushuizen: Nothing to Disclose 2044 EMPAGLIFLOZIN REDUCES LIVER FIBROSIS CAUSED BY CCL4: UNDERSTANDING THE MECHANISM Fushuang Ha 1 Tao Han 2 Junjun Cai 3 Junqing Yan 3 Yin Gu 4 , 1 The Third Central Hospital of Tianjin, 2 Tianjin Union Medical Center, Naikai University Affiliated Hospital, 3 Tianjin Third Central Hospital, 4 Tianjin NaiKai Hospital Background: Liver fibrosis is a reversible response to liver damage and inflammation caused by chronic factors
This approach of requiring manufacturers to report such information would be consistent with CMS' understanding of the provisions of section 1860D-14B of the Act requiring CMS to establish the payment amount benchmark period at the dosage form and strength level, and with CMS' authority under sections 1102(a) and 1871(a)(1) of the Act to make rules and regulations as necessary for the efficient administration of programs, including the Medicare Part D Drug Inflation Rebate Program
